# Junta clínica — PT-pseudo_4a2fa7bc3595 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_4a2fa7bc3595",
  "pid": "PT-pseudo_4a2fa7bc3595",
  "task": 1,
  "psa": 6.9,
  "age": 67,
  "months": 3,
  "pirads": "5",
  "psad": 0.257,
  "psav": -0.62,
  "psap": 5.6,
  "vol": 26.9,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.84531116,
  "medhx": "Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "metformin, empagliflozin, paracetamol PRN",
  "notes": "PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.",
  "pmhx": [
    "Type 2 diabetes",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "172 cm",
    "bmi": "23.7",
    "bp": "106/78 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (16 pack-yr, quit 2006)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels."
    },
    {
      "s": "History",
      "t": "At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement."
    }
  ],
  "occupation": "retired electrical engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Endocrine — thyroid screening",
    "Sleep clinic — suspected obstructive sleep apnoea"
  ],
  "alcohol": "3 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4a2fa7bc3595
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.9 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.257 ng/mL²
  - PSA velocity: -0.62 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 26.9 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84531116 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Type 2 diabetes, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: metformin, empagliflozin, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 6.9 ng/mL. PI-RADS 5. PSAD 0.26. Prostate volume 27 mL. DRE nodus. csPCa 0.85.

Vitals: weight 70 kg, height 172 cm, BMI 23.7, BP 106/78 mmHg, HR 71 bpm. Smoking: Ex-smoker (16 pack-yr, quit 2006).

Chief complaint: Assessment requested to review previous biopsy results alongside recent changes in prostate-specific antigen levels.

History: At 67 years of age, this retired electrical engineer initially entered diagnostic evaluation in early 2023 due to elevated prostate-specific antigen levels. Chronic conditions include type 2 diabetes, controlled through metformin and empagliflozin, as well as osteoarthritis managed with paracetamol taken only when necessary. He shares his home with his married partner and sustains a daily 45-minute walking habit, limiting alcohol intake to approximately three weekly units. A substantial smoking history of 16 pack-years existed until cessation in 2006. Urological interventions remain limited to the initial systematic biopsy that confirmed malignancy. Lower urinary tract symptoms manifest only as occasional mild frequency, aligning with established benign prostatic hyperplasia. He denies urinary retention or hematuria. Recent primary care activities included routine thyroid screening, while suspected obstructive sleep apnoea is currently addressed via positional therapy and pending specialist review. Functional independence remains fully preserved across all daily activities.

Physical examination: DRE — texture: firm, asymmetry: present. A discrete 1.5 cm mass is palpable within the right peripheral zone, consistent with a localized Nodus. The remaining prostatic tissue feels smooth and elicits no tenderness upon palpation. Systemic examination shows stable hemodynamics, clear lung fields, and an absence of peripheral lymph node enlargement.

Patient info: retired electrical engineer; Married; Lives with partner.
Next of kin: Sibling (sister).

Lifestyle: alcohol 3 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Sleep clinic — suspected obstructive sleep apnoea.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.64
  uncertainty  +/- 0.14 (95% CI 0.37-0.91); among patients it cannot tell apart the outcome was 0.94 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a repeat biopsy after a negative biopsy should be considered dependent on risk factors such as PSA density and PI-RADS score. It states, "follow-up or direct repeat biopsy should be considered dependant of risk factors (e.g. PSA density, PI-RADS score)."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the specific thresholds the guideline sets. Specifically, the classifier did not incorporate the specific thresholds for PSA density and PI-RADS score that the guideline uses to determine the need for a repeat biopsy.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 5, which is a high-risk finding, which suggests a need for further investigation according to the guideline.
PSA density - The PSA density is 0.257 ng/mL², which is a value that the guideline uses as a risk factor to determine the need for a repeat biopsy.
Prior biopsy status - The prior biopsy status is 'Positive', which is a critical factor that the guideline uses to guide the decision pathway.
Prior biopsy status - The prior biopsy status is 'Positive', which is a critical factor that the guideline uses to guide the decision pathway.
Prior biopsy status - The prior biopsy status is 'Positive', which is a critical factor that the guideline uses to guide the decision pathway.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on incorporating the specific risk factors outlined in the EAU guideline, particularly the PI-RADS score and PSA density, to determine the next step given the prior positive biopsy.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> To determine the mpMRI prose, including lesion size, zone, and extraprostatic extension.
  psa_trend (get_psa_trend) -> To determine the serial PSA values and trend.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the mpMRI prose to confirm the PI-RADS score and assess for extraprostatic extension?
  Q2. What is the PSA trend to assess the rate of change in PSA?
  Q3. What is the laboratory results panel to confirm all relevant metrics?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose shows a PI-RADS 5 lesion in the right peripheral zone with dimensions of roughly 14 by 11 by 10 mm, and the prostate volume is 26.9 mL, yielding a PSA density of 0.257 ng/mL/mL.
psa_trend
The PSA trend shows serial values: 2.3 ng/mL on Apr 2023, 4.0 ng/mL on Mar 2024, and 6.9 ng/mL on Feb 2025.

WHAT I DID NOT OPEN
laboratory_results panel was left closed because the moderator stated it was requested without naming a specific metric that justified it.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose shows a PI-RADS 5 lesion, which suggests a need for further investigation according to the EAU guideline.
The PSA trend shows a rising trend in PSA, with the most recent value being 6.9 ng/mL.

AGAINST sampling this patient now
The prior biopsy status is 'Positive', which is a critical factor in the cohort data.

WHERE THIS LEANS
The combination of a high PI-RADS score and a rising PSA trend strongly supports further investigation according to the guideline, despite the prior positive biopsy.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 and Q2 by providing the mpMRI prose and the PSA trend, but Q3 regarding the laboratory results panel remains unanswered as the panel was not opened.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the Expert-Classifier's suggestion of biopsy because the mpMRI prose shows a PI-RADS 5 lesion, and the PSA trend shows a rising trend, both of which the EAU guideline highlights as risk factors.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the mpMRI prose to confirm the PI-RADS score and assess for extraprostatic extension? Answered by the registrar with the description of a PI-RADS 5 lesion.
Q2. What is the PSA trend to assess the rate of change in PSA? Answered by the registrar with serial values showing a rising trend.
Q3. What is the laboratory results panel to confirm all relevant metrics? Not answered; the panel remains closed.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score because it indicates the likelihood of clinically significant cancer, the PSA density because it is a risk factor for repeat biopsy, and the prior biopsy status because it is a critical factor in the cohort data. The room has been leaning on the rising PSA trend, which the guideline supports, but the guideline does not explicitly support the decision given the prior positive biopsy.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the high PI-RADS score and rising PSA trend, as detailed in the retrieved reports, meet the criteria for further investigation according to the EAU guideline, despite the prior positive biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: laboratory_results

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Despite the prior positive biopsy, the high PI-RADS 5 score and the rising PSA trend strongly support further investigation per the EAU guideline. The combination of a PI-RADS 5 lesion and a rising PSA trend, which the registrar retrieved, justifies a repeat biopsy to determine the current status for management. The room converged on proceeding with a biopsy based on these objective findings.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend
